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Abstract
siRNA therapeutics has developed rapidly and already there are clinical trials ongoing or planned; 
however, the delivery of siRNA into cells, tissues or organs remains to be a major obstacle. Lipid-
based vectors hold the most promising position among non-viral vectors, as they have a similar 
structure to cell or organelle membranes. But when used in the form of liposomes, these vectors 
have shown some problems. Therefore, either the nature of lipids themselves or forms used should 
be improved. As a novel class of lipid like materials, lipidoids have the advantages of easy 
synthesis and the ability for delivering siRNA to obtain excellent silencing activity. However, the 
toxicities of lipidoids have not been thoroughly studied. pH responsive lipids have also gained 
great attention recently, though some of the amine-based lipids are not novel in terms of chemical 
structures. More complex self-assembly structures, such as LPD (LPH) and LCP, may provide a 
good solution to siRNA delivery. They have demonstrated controlled particle morphology and size 
and siRNA delivery activity for both in vitro and in vivo.
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Introduction
RNA interference (RNAi) was discovered by Fire et al. (1998) who demonstrated that 
double-stranded RNA is much more effective at producing interference than either strand 
individually and that interference occurs at the post-transcriptional level. It has been 
recognized as ‘one of the most exciting discoveries in biology in the last couple of years’ 
(Jana, 2004). The potent gene silencing in a sequence specific manner has caused it to attract 
much attention for applications to biosciences and medicines (John, 2007; Karagiannis, 
2005; Geisbert, 2010; Pan, 2011). RNAi is a naturally occurring process that mediates 
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sequence specific inhibition of gene expression through the activation of a protein complex 
called RNA-induced silencing complex (RISC). RNAs in RISC are small duplex molecules 
termed siRNAs (21–23nt) produced through the cleavage of long dsRNAs (Zamore, 2000). 
The RISC cleaves the target mRNA at a sequence-specific position, guided by the antisense 
strand of the siRNA. It has been recognized that the siRNA strand incorporated into RISC is 
recycled, thus repeatedly down-regulating gene expression with only a small amount of 
siRNA. The entire process occurs within the cytoplasm of the cell, thus circumventing the 
need for nuclear delivery and alleviating concerns over the direct modification of the host 
genome. Therefore, researchers have paid considerable attention for its potential to down-
regulate genes for therapies (Tan, 2011). This is especially the case for the ‘undrugable 
targets’.
Though siRNAs have advantages over the long dsRNAs, such as being easily prepared by 
chemical methods and easily handled during biological assays, they still exhibit the 
problems of poor membrane permeability and nuclease resistance which limit their 
applicability to therapeutic use. Therefore, RNAi therapeutics requires suitable delivery 
vehicles for both in vitro and in vivo applications (Perkel, 2009). The success of RNAi 
critically depends on suitable delivery vectors that have the high efficiency transfer of 
siRNA to target cells, as well as a favourable safety profile. An ideal vehicle for cancer 
therapy should meet at least four major criteria: the evasion of the mononuclear phagocytic 
system (MPS), extravasation from the blood circulation into the tumor, diffusion through the 
extracellular matrix to bind with tumor cells, and escape from the endosome to release the 
cargo siRNA into the cytoplasm (Whitehead, 2009; Wang, 2012).
Broadly, the vectors are classified mainly into two categories: viral and non-viral (Liu, 
2002). The successful application of siRNA, is largely dependent on the development of a 
delivery vehicle which should be administered efficiently, safely, and repeatedly, if needed. 
Viral systems usually give high transfection efficiencies, but safety concerns from potential 
mutation, recombination, oncogenic effect and high cost greatly limit their therapeutic 
applications. In contrast, non-viral vectors are believed to cause fewer safety problems due 
to their relative simplicity. Lipids have long been known to be the most promising vectors, as 
they are amphiphilic molecules that spontaneously assemble into micelles or bilayers. An 
extensive range of lipids for the delivery of siRNA have been developed, though nonspecific 
cytotoxicity associated with cationic liposomes has been observed (Farhood, 1992; 
Romoren, 2004; Scales, 2006).
Since the first description of successful in vitro transfection with a cationic lipid by Felgner 
et al in 1987 (Felgner, 1987), numerous cationic lipids have been synthesized and used for 
delivery of nucleic acids into cells during the last 25 years (Adrian, 2010; Mével, 2010; Tao, 
2010; Guo, 2011; Sparks, 2012). Cationic lipids were first used in the form of liposomes, as 
they could improve the gene delivery efficacy owing to their typical bilayer structure when 
forming lipoplexes with nucleic acids. Some helper lipids (co-lipids) such as cholesterol, 
dioleylphosphatidyl choline (DOPC) or dioleylphosphatidyl ethanolamine (DOPE), typically 
neutral lipids (Zuhorn, 2005), are often employed with cationic lipids. They play a very 
important role during the formation of lipoplexes by combining cationic liposomes and 
siRNA, as they could determine the morphology of lipoplex. Many reviews (Zabner, 1997; 
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Woodle, 2001; Zabner, 2002; Zhang, 2004) discussing cationic liposomes for plasmid DNA 
delivery are available. It seems that cationic lipids combined with co-lipids could not meet 
the requirements of siRNA delivery in spite of the fact that a large amount of compounds 
have been explored.
A brief overview of lipid based liposomes related to siRNA delivery
Since the pioneer work in the late 1980s, a large amount of papers have been published on 
the delivery of genetic materials via liposomes (Malone, 1989). There are a number of 
commercially available cationic liposome/lipid based systems, such as DOTAP, Lipofectin, 
RNAifect, Oligofectamine, Lipofectamine and TransIT TKO (Omidi, 2003; Gilmore, 2004; 
Khan, 2004; Judge, 2005; Morrissey, 2005; Pirollo, 2007). One of the earliest lipoplexes 
developed for nucleic acid delivery is the commercially-available Lipofectin (Felgner, 1987). 
This formulation of cationic liposomes, assembled from a mixture of N -[1-(2,3-
dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) and DOPE, 
demonstrated successful transfection with mRNA for a broad range of cell lines (Malone, 
1989). The formulation has also shown successful transfection with siRNA for human cell 
lines (Beale, 2003). DOTAP (N-[1-(2,3-dioleoyloxy)]-N,N,N -trimethyl ammonium 
propane) and Oligofectamine were some of the first lipid formulations to be used for the in 
vivo delivery of siRNA and effective gene silencing of tumor necrosis factor α (TNF-α) and 
β-catenin in mice (Sorensen, 2003; Verma, 2003). Fluorescein-labeled siRNA was injected 
into adult mice to investigate cationic liposome-mediated intravenous and intraperitoneal 
delivery. The results showed that DOTAP containing liposomes can deliver siRNA into 
various cell types. Unlike in mouse cells, these siRNA can activate the nonspecific pathway 
in human freshly isolated monocytes to produce TNF-α and IL-6 (Sioud, 2003). Sorensen et 
al. (2003) also used cationic DOTAP liposomes to inject siRNA against TNF-α resulting in a 
suppression of the lethal reaction to lipopolysaccharide (LPS) injections in a mouse model 
of sepsis. Additionally, successful silencing of a marker gene (GFP) in liver cells after 
intravenous injection of liposomes was reported. Flynn et al. (2004) used Lipofectamine to 
deliver IL12-p40siRNA to target the expression of IL12-p40 in a model of LPS-induced 
inflammation. Significant reduction of immune reaction in treated animals was obtained, 
presumably via reduced IL12 production in peritoneal macrophages.
Many other non-commercial cationic lipids are being investigated for promising uses both in 
vitro and in vivo. For example, Khoury et al. (2006) demonstrated cationic lipid 2-(3-[Bis-
(3-amino-propyl)-amino]-propylamino)-N-ditetradecylcarbamoylme-thylacetamide 
(RPR209120) combined with DOPE can efficiently deliver siRNA designed to silence TNF-
α in collagen-induced arthritis. Similarly, Sato et al. (2007) indicated that a galactosylated 
liposome/siRNA complex could induce silencing of endogenous hepatic gene expression 
with no observed liver toxicity. Grinstaff and co-workers connected nucleosides with alkyl 
chains to create nucleoside lipids for gene (Chabaud, 2006) and siRNA (Ceballos, 2009) 
delivery in a human liver cell line. The unique feature of this concept is that the system has 
been designed to be charge-reversible (Tan, 2011). Akinc et al. (2008) designed and 
synthesized a large amount of compounds called lipidoids which could show promising 
applications in the future. One method for improving the efficiency of transfection is to link 
lipophilic siRNA to lipid moieties (e.g. derivatives of cholesterol, lithocholic acid or lauric 
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acid). The lipid moieties are covalently linked to the 5′-ends of the RNAs using 
phosphoramidite chemistry. It was found that siRNA with a modified sense strand down-
regulated β-galactosidase expression to a higher extent than either siRNA with a modified 
antisense strand or two modified strands (Lorenz, 2004).
PEGylation is a successful way to improve pharmacokinetics of siRNA in vivo and to form 
‘stealth’ liposomes (SL). PEGylated liposomes are a clinically approved delivery system for 
doxorubicin, and therefore represent a viable option for delivering siRNA in humans 
(Zimmermann, 2006). When dipalmitoylphosphatidylcholine (DPPC), 
dipalmitoylphosphatidylglycerol (DPPG) and dipalmitoylphosphatidylethanolamine-
polyethyleneglycol2000 (DPPE-PEG2000) were combined to prepare DPPG:DPPC:DPPE-
PEG2000 SL, entrapped siRNA targeting enhanced green fluorescent protein (EGFP) did 
not silence gene expression of HeLa-cells stably expressing EGFP. However, preliminary 
flow cytometry and confocal microscopy data showed that the SL siRNA formulation 
increased uptake of siRNA into vesicular compartments of HeLa cells in a concentration-
dependent manner that could be augmented by exogenous sPLA2. SL can also be used to 
apply target siRNA to inflamed tissue for silencing cytokine expression in rheumatoid 
arthritis (Foged, 2007).
Even after many years of research, lipoplex still needs to be improved in terms of both 
stability and toxicity to cells. Though the stability and delivery efficiency of lipoplex can be 
enhanced by increasing the ratio of cationic lipid to siRNA, it can also lead to an increase in 
cytotoxicity (Ozpolat, 2010). Some solutions have been suggested. For example, pentavalent 
cationic lipoplexes have been used for siRNA delivery. These multivalent lipids exhibited 
not only a higher silencing efficiency than monovalent lipids, but also a lower cytotoxicity 
by minimizing the amount of lipids required for complex formation (Bouxsein, 2007).
Though cationic liposome-mediated RNAi has become popular in recent years, not all 
responses are positive. The large proportion of ‘unused’ RNA molecules could become toxic 
for cells or trigger a response that could change cell metabolism (Barreau, 2006). Clearly, 
our understanding of liposome delivery of siRNA is still evolving, and more research is 
needed. Given more research, especially regarding experiments done in vivo, liposome 
delivery may be developed into a promising tool for therapeutic application of siRNA (Li, 
2006a). For this reason, we will focus on two promising classes of lipids: lipidoids and pH 
responsive lipids. To overcome the drawbacks of lipoplex, researchers have assembled 
different nanostructures such as lipid-protamine-DNA (LPD), lipid-calcium-phosphate 
(LCP), solid lipid nanoparticles (SLN) and stable nucleic acid-lipid particles (SNALP) based 
on lipids. We will illustrate examples of these self-assembled structures. The aim is to build 
a bridge between lipids and controlled assemblies for facilitating the use of lipids for siRNA 
delivery.
pH-responsive cationic lipids
pH-responsive lipids for efficient drug/gene delivery have attracted increasing attention in 
the past decade. Tertiary amines have long been used for the delivery of genes, but have been 
found to have more uses regarding response to the pH of cells. For example, Spelios (2007) 
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synthesized cationic lipids by using bis-(2-dimethylaminoethane) and mono-(2-
dimethylaminoethane) as head groups through the linkage of a carbamate bond (Figure 1). 
The bis-heads lipids were more ionizable than mono-head ones; the pH-expandable polar 
head-groups and greater intramolecular distance between the hydrophobic chains formed 
assemblies that resulted in high transfection activity. Efficient binding and compaction of 
pDNA, increased acyl chain fluidity, and high molecular elasticity all contributed to the high 
transfection activity. However, the authors did not mention any effects of carbamate on the 
physicochemical properties and transfection efficiency, as carbamate itself is a pH dependent 
group. When incorporating a carbamate group into the linker, it may be assumed that the pH 
decrease will act as a trigger, disconnecting the hydrophobic and hydrophilic portions of the 
lipoplex, releasing DNA after entering endosomes within the cell (Liu, 2005a). We 
synthesized carbamate-linked cationic lipids for liposome-mediated gene delivery, which 
proved to have good gene transfection properties in different cell lines. As they are 
chemically stable and biodegradable, many cationic lipids of this kind have been synthesized 
(Liu, 2005a; Liu, 2005b; Liu, 2008; Zhao, 2011). To maintain the balance between serum 
stability and transfection efficiency, Chan et al. (2012a, 2012b) have designed and 
synthesized a hydrolysable acid-labile PEG-lipid (HPEG-lipid, PEG MW 2000). This PEG-
lipid was stable at physiological pH, but was cleaved at a low pH; the HPEG-lipid was stable 
at a neutral pH for more than 24 h, but degraded completely within 1 h at pH 4, leading to 
particle aggregation. HPEG-lipoplexes showed lower toxicity and enhanced transfection in 
comparison to lipoplexes stabilized with pH-stable PEG-lipids. Live-cell images showed that 
both pH-sensitive and pH-stable PEG-lipoplexes were internalized to quantitatively similar 
particle distributions within the first 2 h of incubation. Thus, the increased transfection of the 
HPEG-lipoplexes can be attributed to efficient endosomal escape, enabled by the novel 
HPEG-lipid.
Based on their previous study of multivalent cationic lipids (MVLn, n = 2 to 5) (Ewert, 
2002; Ahmad, 2005; Bouxsein, 2007), Shirazi et al. (2011) put a disulfide bond spacer 
between the headgroup and lipophilic tails of MVLn lipids to give a series of degradable 
vectors (CMVLn) for gene delivery. This spacer would respond to the reducing milieu of the 
cytoplasm and be cleaved to decrease lipid toxicity. Among these degradable lipids, CMVL4 
and CMVL5 (Figure 2) showed transfection efficiency comparable to MVL5 and some 
commercial transfection reagents while also having lower toxicity to cells. These results 
demonstrated that degradable disulfide spacers may be used to reduce the cytotoxicity of 
synthetic nonviral gene delivery carriers without compromising their transfection efficiency. 
Although the disulfide bond incorporated into cationic lipids for pH-based response is not a 
novel idea (Jiang, 2010), there is still a relatively positive impact on the decreased toxicity 
elicited. This research therefore appears to be very promising opportunity for further lipid 
design utilizing disulfide bonds for enhancing the performance of siRNA delivery vectors. 
For example, a new series of cholesterol-disulfide lipids bearing cholesterol and a variety of 
head groups via disulfide and carbonate bond linkages have been synthesized. The results 
demonstrated low cytotoxicity, strong pDNA binding affinity, high transfection, particularly 
high intracellular uptake capability, and specific cellular localization of pDNA at the 
periphery of cell nuclei for newly prepared CHOSS lipids (Figure 3) (Sheng, 2011).
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Based on the work of pH-responsive lipids for gene delivery Semple et al. (2010) 
synthesized a series of pH-responsive lipid molecules that contain ionizable amine-based 
head groups, which could efficiently formulate nucleic acids at a low pH and maintain a 
neutral or low cationic surface charge density at pH 7.4. By maintaining this surface charge 
density, the amine head group provides a longer half-life in circulation and reduces 
nonspecific cytotoxicity. Once reaching the acidic environment of the endosome, the head 
group should become protonated and positively charged so as to be available for ion pairing 
with the negatively charged endosomal lipids. The best-performing lipid, DLin-KC2-DMA 
(Figure 4), containing two cis double bonds per hydrocarbon chain, a tertiary amine head 
group and a ketal-ring linker, was formulated into SNALP. This lipid was shown to be well-
tolerated in both rodents and non-human primates, exhibiting in vivo activity at siRNA doses 
as low as 0.01 mg/kg in rodents, as well as the silencing of a therapeutically significant gene 
(TTR) in nonhuman primates. Lipids showing pH-responsive ability are successful both in 
vitro and in vivo; their low toxicity and low dose of siRNA in the formulations may lead 
them to clinical success.
Lipidoids
Akinc (2008) synthesized a library of over 1200 lipid-like materials through the conjugate 
addition of an amine to an acrylate or acrylamide, termed lipidoids (Figure 5). Depending on 
the number of addition sites in the amino monomer, lipidoids can be formed 1 to 7 tails. The 
advantage of this method is the one-step synthetic scheme which enables the straightforward 
parallel generation of large libraries of delivery materials. The safety and efficacy of 
lipidoids were evaluated for siRNA delivery performance in three animal models: mice, rats 
and nonhuman primates. Therapeutic efficacy was observed in vivo in liver, lung and 
peritoneal macrophages. The author concluded that certain design criteria were necessary for 
creating future intracellular delivery agents, including (i) amide linkages, (ii) more than two 
alkyl tails, (iii) tail length in the range of 8–12 carbons and, (iv) a secondary amine. The 
study suggests that these materials may have broad utility for both local and systemic 
delivery of RNA therapeutics.
Based on one of the novel lipid-like materials, 98N12-5(1) (Figure 6), the group obtained a 
final optimized formulation (LNP01). LNP01 has a lipid composition of 
98N12-5(1):cholesterol:PEG lipid = 42:48:10 (mol:mol:mol), total lipid:siRNA = ~7.5:1 
(wt:wt), C14 alkyl chain length on the PEG lipid, and a particle size of roughly 50–60 nm. It 
has been used successfully to silence multiple (>10) genes in several species (i.e. mouse, rat, 
hamster, and monkey). The lead formulation developed was liver targeted (>90% injected 
dose distributes to liver) and can induce fully reversible, long-duration gene silencing 
without a loss of activity following repeat administration (Akinc, 2009). Huang et al. (2009) 
used these lipidoids to deliver CLDN3 siRNA in 3 different ovarian cancer models. Their 
results suggested intratumoral injection of lipidoid/CLDN3 siRNA into OVCAR-3 
xenografts resulted in dramatic silencing of CLDN3, significant reduction in cell 
proliferation, reduction in tumor growth, and a significant increase in the number of 
apoptotic cells. Furthermore, intraperitoneal injection of lipidoid-formulated CLDN3 siRNA 
resulted in a substantial reduction in tumor burden in MISIIR/Tag transgenic mice and mice 
bearing tumors derived from mouse ovarian surface epithelial cells. Toxicity was not 
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observed after multiple i.p. injections and treatment of mice with nonimmunostimulatory 2′-
OMe modified CLDN3 siRNA was as effective in suppressing tumor growth as unmodified 
siRNA. This method may provide a therapeutic solution to ovarian cancer.
After the first library of lipidoids was proved effective for delivery of siRNA, Love (2010) 
made an epoxide-derived lipidoid library through combinatorial synthesis (Figure 7). A 
formulation has been identified that enabled siRNA-directed liver gene silencing in mice at 
doses below 0.01 mg/kg. After a single injection, this formulation was shown to specifically 
inhibit expression of five hepatic genes simultaneously. The potential of this formulation 
was further validated in nonhuman primates, where high levels of knockdown of the 
clinically relevant gene transthyretin were observed at doses as low as 0.03 mg/kg. Further, 
they synthesized materials of lipid-like tails and feature appendages containing hydroxyl, 
carbamate, ether, or amine functional groups as well as variations in alkyl chain length and 
branching (Figure 8). The relationship between lipid chemical modification and delivery 
performance in vitro was studied using a luciferase reporter system in HeLa cells to show 
the impact of the functional group depending on the overall amine content and tail number 
of the delivery vectors (Mahon, 2010).
More recently, binary combinations of these ionizable, lipid-like materials have been used to 
synergistically achieve gene silencing (Whitehead, 2011). They found that ineffective, 
individual lipid-like materials could be formulated together in a single delivery vehicle to 
induce near-complete knockdown of firefly luciferase and factor VII in HeLa cells and in 
mice, respectively. Among the 3,780 formulations that were made through 630 binary pairs 
of 36 synthetic lipidoids, the combinations of 86N15–98O13 were chosen as representatives 
to demonstrate the synergistic action by mediated cellular uptake and endosomal escape. 
The data indicated that formulating lipid-like materials in combination can significantly 
improve siRNA delivery outcomes while also increasing the material space available for 
therapeutic development. Research demonstrates the binary formulation strategy could be an 
important technique for siRNA or other nucleic acid delivery.
Hybrid siRNA delivery systems based on lipids
Since cationic lipids were successfully used for the delivery of nucleic acids, researchers 
have been designing and synthesizing a large amount of new compounds (Arpicco, 2004; 
Bianco, 2005). However, they do not function well in terms of transfection efficiency, 
leading to the development of hybrid delivery systems based on lipids. At first, helper lipids 
were incorporated in the systems to yield high transfection efficiency through controlling the 
morphology (Ma, 2007) of lipoplex and destabilizing the endosome membrane (Farhood, 
1995). Later, various lipid-based nano-assemblies including LPD (Li, 2006b), LCP (Li, 
2010), SNALP (Heyes, 2005; Morrissey, 2005), and SLN, were produced through the 
combined use of lipids, proteins, polymers, inorganic particles and other materials. These 
nano-assemblies are believed to be much more uniform in size than lipoplex and have the 
ability to escape from clearance to enter into targeted cells. Hence, more of these assemblies 
are entering the clinical trial phase.
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Gao (1996) discovered that several cationic polymers with high molecular weights, such as 
poly(L-lysine) and protamine, can enhance the transfection efficiency of some cationic 
liposomes by 2–28-fold in a number of cell lines in vitro. This discovery was based on a 
report that some polycations, such as polylysine, histone, and protamine, can effectively 
condense DNA to about 30–100 nm in diameter (Wagner, 1991). It was then found that the 
condensation agent protamine sulfate USP was superior to poly-L-lysine and other types of 
protamine (Sorgi, 1997). At the same, LPD was used to transfer DNA in vivo. The optimal 
dose was approximately 50 mg per mouse at which a concentration of approximately 20 ng 
luciferase protein per milligram extracted tissue protein could be detected in the lung (Li, 
1997).
Based on the study of DNA delivery by using LPD, the formulation was extended for the 
delivery of siRNA. AS-ODN or siRNA against human survivin was mixed with a carrier 
DNA (calf thymus DNA) before complexing with protamine. The resulting particles were 
coated with cationic liposomes, consisting of DOTAP and cholesterol, to obtain LPD 
nanoparticles. Finally, ligand targeting and steric stabilizing components were incorporated 
into the preformed LPD nanoparticles using DSPE-PEG-anisamide. It was found that tumor 
cell delivery and antisense activity of PEGylated nanoparticles were sequence dependent and 
rely on the presence of the anisamide ligand. The uptake of oligonucleotide in targeted, 
PEGylated nanoparticles could be completed by excess free ligand. The results suggest that 
the ligand-targeted and sterically-stabilized nanoparticles can provide a selective delivery of 
AS-ODN and siRNA into lung cancer cells, down-regulate survivin, and sensitize the cells to 
anticancer drugs (cisplatin) (Li, 2006b; Li, 2006c).
The systemic in vivo study using the ligand targeted, PEGylated LPD formulation showed 
significant increase in cellular uptake via the specific receptor-mediated pathway. It was 
estimated that both LPD-PEG and LPD-PEG-AA could deliver a large fraction of the 
injected dose per gram of organ weight. Nonspecific reticuloendothelial system (RES) 
uptake causes the majority of losses of the administered dose. This targeted formulation also 
demonstrated a strong gene-silencing effect mediated by RNAi. Data showed that the 
surface-modified LPD delivered siRNA predominantly to the tumor after intravenous 
administration. The formulation provided an advantage of high tumor targeting and low RES 
uptake, which implied its potential for RNAi-based tumor therapy (Li, 2006c).
Further, LPD formulation was used to target metastasis model tumors with sigma receptor–
expressing murine melanoma cells, B16F10. The lung metastasis model was established by 
intravenous (IV) injection of the B16F10 cells into C57BL/6 mice. In B16F10 melanoma 
cells targeted nanoparticles (NP) showed a 4-fold increase in delivery efficiency compared to 
non-targeted NP. Simultaneous silencing of three oncogenes in the metastatic nodules was 
obtained using siRNA against MDM2, c-myc, and vascular endothelial growth factor 
(VEGF) co-formulated in the targeted LPD. Two consecutive IV injections of siRNA in the 
targeted NP significantly reduced the lung metastasis (~70–80%) at a relatively low dose 
(0.45 mg/kg), whereas free siRNA and the non-targeted nanoparticles showed little effect. 
The targeted NP formulation prolonged the mean survival time of the animals by 30%, 
compared to the untreated controls. At the therapeutic dose, the targeted NP showed little 
Zhang et al. Page 8













local and systemic immunotoxicity and did not decrease the body weight or damage the 
major organs (Li, 2008a). In the subsequent study (Li, 2008b), the dose was decreased to 
0.15 mg/kg, and resulted in 70–80% gene silencing in the whole lung metastasis. The 
toxicity of the NP formulations was evaluated by their induction of the proinflammatory 
cytokines (IL6, IL12, TNF, IFN-α). None of the NP formulations were immunotoxic. 
Additionally, no body weight decrease was observed for any of the mice treated with the 
formulations.
The formulations were improved by the replacement of calf thymus DNA with hyaluronic 
acid. In this procedure, protamine and a mixture of siRNA and hyaluronic acid were mixed 
to prepare a negatively charged complex. Then, cationic liposomes were added to coat the 
complex with lipids via charge-charge interaction to prepare the LPH NP. LPH was further 
modified by DSPE-PEG or DSPE-PEG-anisamide using the postinsertion method. The 
particle size, zeta potential, and siRNA encapsulation efficiency of the formulation were 
approximately 115 nm, +25 mV and 90%, respectively. LPH silenced 80% of luciferase 
activity in the metastatic B16F10 tumor in the lung after a single IV injection (0.15 mg 
siRNA/kg), nearly the same amount as the corresponding LPD formulation. However, the 
targeted LPH showed very little immunotoxicity in a wide dose range (0.15–1.2 mg siRNA/
kg), while the LPD (liposome-protamine-DNA nanoparticle) had a relatively narrow 
therapeutic window (0.15–0.45 mg/kg). The ED50 for the luciferase silencing in the B16F10 
melanoma model was 75 μg/kg in siRNA, but the induction of both IL-6 and IL-12 cytokines 
by LPH was significantly lower than that of the corresponding LPD formulation (Chono, 
2008; Gao, 2009). Later, the LPH formulation was modified with tumor-targeting, single-
chain antibody fragment (scFv) for systemic delivery of siRNA and microRNA (miRNA) 
into experimental lung metastasis of murine B16F10 melanoma. The siRNAs delivered by 
the scFv targeted nanoparticles efficiently down-regulated the target genes (c-Myc/MDM2/
VEGF) in the lung metastasis. Two daily IV injections of the combined siRNAs in the scFv-
targeted nanoparticles significantly reduced the tumor load in the lung. In this study, it was 
first reported that miR-34a and siRNA were co-formulated in scFv-targeted nanoparticles to 
obtain an enhanced anticancer effect (Chen, 2010c).
The replacement of DOTAP with DSGLA (a nonglycerol based cationic lipid which contains 
both a guanidinium and a lysine residue as the cationic headgroup) in LPD caused an 
increase in efficiency of the down-regulation of pERK in H460 cells. A synergistic cell-
killing effect in promoting cellular apoptosis was also observed with DSGLA in the 
formulation. The fluorescently labeled siRNA was efficiently delivered into the cytoplasm of 
H460 xenograft tumor by the LPD-PEG-AA containing either DOTAP or DSGLA 4 h after 
IV injection. Three daily injections (0.6 mg/kg each) of siRNA could effectively silence the 
epidermal growth factor receptor (EGFR) in the tumor, but the formulation containing 
DSGLA induced more cellular apoptosis. Hence, a significant improvement in tumor growth 
inhibition has been observed after dosing with LPD-PEG-AA containing DSGLA (Chen, 
2009).
Another formulation is the use of N,N-distearyl-N-methyl-N-2-(N′-arginyl) aminoethyl 
ammonium chloride (DSAA) liposome to coat the polyplex cores for delivering a c-Myc 
siRNA into the cytoplasm of B16F10 murine melanoma cells. Significant tumor growth 
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inhibition was observed with nanoparticles composed of DSAA with DOTAP. Three daily 
injections of c-Myc siRNA formulated in this way could impair tumor growth, with an ED50 
of about 0.55 mg/kg. Additionally, it was found that the targeted DSAA nanoparticles 
containing c-Myc siRNA sensitized B16F10 cells to paclitaxel (Taxol), caused a complete 
inhibition of tumor growth for 1 week. Treatments of c-Myc siRNA in the targeted 
nanoparticles containing DSAA also showed significant inhibition on the growth of MDA-
MB-435 tumor (Chen, 2010b).
Two formulations, LPD and LPD-II (anionic liposome formulation), were used for systemic 
co-delivery of doxorubicin (Dox) and a therapeutic siRNA to multiple drug resistance 
(MDR) tumors. The results showed that both multifunctional nanoparticle formulations 
could deliver Dox and siRNA to MDR tumors simultaneously. Though siRNA and Dox 
delivered by targeted LPD and LPD-II showed similar apoptosis inductions and therapeutic 
efficacies, LPD nanoparticles containing DSAA induced more toxicity compared with LPD-
II nanoparticles. Compared with the LPD nanoparticles, the LPD-II nanoparticles could also 
carry more Dox in the formulation. Therefore, LPD-II nanoparticles with higher entrapment 
efficiency of Dox and a lower toxicity profile may show a larger therapeutic window and a 
greater potential for clinical application for cancer therapy (Chen, 2010a).
The LPD (including LPH) formulations are more successful than other formulations (e.g. 
lipoplexes). The differences in the components of the delivery systems highlight this 
success. Cationic lipids and protamine can interact with negatively charged siRNA to form 
liposome-coated nanoparticles. The introduction of PEG provides surface steric stabilization 
to prevent the aggregation of the resulting complex with serum components. A large amount 
of PEG could be grafted to the NP surface as the result of the improved stability of the lipid 
bilayer due to charge-charge interaction with the core. The thick PEG layer at the NP surface 
gives the ability of the NP to evade RES (Li, 2009). The anisamide ligands are attached to 
the distal end of the PEG chain to increase cellular target. Cationic lipids are also necessary 
for endosome lysis and intracellular release of siRNA. The mechanism of the endosome 
membrane destabilization is most likely due to the formation of ion pair complex between 
the cationic lipids in the nanoparticles and the negatively charged anionic lipids in the 
endosome membrane. The versatile choice of lipids and polymers (such as protamine and 
hyaluronic acid), the co-delivery of siRNA, and chemodrugs are attractive features of this 
type of formulation to create solutions for the delivery of siRNA.
LCP
Although LPD showed success in delivering siRNA after IV injection, improvements were 
needed to address the low siRNA release efficiency and moderate toxicity. It has been shown 
that the release of siRNA into the cytoplasm is variable depending on the cell. To improve 
the cargo release in the target cells, the core of the nanoparticle of LPD was replaced with a 
biodegradable and acid-sensitive calcium phosphate (CaP) nanoprecipitate to give a new 
delivery formulation, LCP. The calcium phosphate core is acid sensitive; therefore, LCP 
disassembles at a low pH in the endosome, causing an osmotic pressure increase, endosome 
swelling and rupture to release the entrapped siRNA (Li, 2010). The increase of intracellular 
Ca2+ concentration shown by using a calcium specific dye, Fura-2, demonstrates the 
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mechanism. The anisamide modified LCP silenced about 70% and 50% of luciferase activity 
for H-460 tumor cells in culture and those grown in a xenograft model, respectively. The 
new LCP formulation improved the in vitro silencing effect 40-fold compared to the 
previous LPD formulation, while maintaining a negligible immunotoxicity. After a single IV 
injection of anti-luciferase siRNA (0.12 mg siRNA/kg) formulated in targeted a LCP 
formulation (exhibiting a 40 nm particle size, a +25 mV zeta-potential, and 91% siRNA 
encapsulation efficiency), luciferase activity in metastatic B16F10 tumor-loaded lungs was 
decreased by 78% in C57BL/6 mice.
Later, the first generation of LCP was improved by using an anionic lipid, dioleoyl 
phosphatydic acid (DOPA), as the inner leaflet lipid to coat the nano-size CaP cores. A 
suitable neutral or cationic lipid was used as the outer leaflet lipid to form an asymmetric 
lipid bilayer structure which was verified by the measurement of NP zeta potential. 
PEGylation of NP was accomplished by including a PEG-phospholipid conjugate, with or 
without a targeting ligand, anisamide, in the outer leaflet lipid mixture. The resulting LCP-II 
had a size of about 25–30 nm in diameter and contained a hollow core, as revealed by TEM 
imaging. The sub-cellular distribution studied in the sigma receptor positive human H460 
lung cancer cells indicated that LCP-II could release more cargo to the cytoplasm than the 
previous LPD formulation, leading to a significant (~40 fold in vitro and ~4 fold in vivo) 
improvement in siRNA delivery. However, a bio-distribution study showed that LCP-II 
required more PEGylation for RES evasion than the previous LPD, probably due to 
increased surface curvature in LCP-II (Li, 2012). In a therapeutic experiment, siRNA against 
MDM2, c-myc, and VEGF co-formulated in the targeted LCP-II resulted in simultaneous 
silencing of the respective oncogenes in metastatic nodules. Treatment with siRNA in the 
targeted NP significantly reduced lung metastases (~70–80%) at a relatively low dose (0.36 
mg/kg). Moreover, this targeted LCP-II NP significantly prolonged the mean survival time 
of the animals by 27.8% compared to the control group without showing any toxicity at the 
therapeutic dose (Yang, 2012).
Conclusion
Lipids are promising and versatile carriers because they can be custom-designed with 
specifically funtional properties which allow for protection of the siRNA, steric stabilization, 
targeting, membrane destabilization and triggered drug release (Foged, 2012). Although the 
cationic lipid-based delivery systems have demonstrated the potential of siRNA as future 
human medicines, they still need more development effort (Oh, 2009). Lipid-based 
liposomes used to deliver siRNA do not have optimal encapsulation efficiency; that is, many 
siRNA molecules stay freely in solutions. If we want to decrease the amount of free siRNA, 
the number of liposomes will need to be increased to cause additional toxicity both in vitro 
and in vivo. The other challenge that remains is the control of morphologies and sizes of 
lipoplexes. Therefore, though as low as 0.01 mg/kg of siRNA dose could silence genes 
efficiently, it was very difficult to advance these formulations into clinical trials. Perhaps the 
controlled assembly of lipids into biodegradable cores with well defined morphology and 
size, such as in the cases of LPD and LCP, could provide a real solution to the problem, 
though relatively high siRNA dose (0.12 or 0.15 mg/kg) is required in mice. To date, most 
studies address proof-of-concept but do not investigate any possible toxicity of the applied 
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siRNA formulations. Lipidic carriers are not only able to increase immune reactions, but can 
also possess intrinsic immunostimulatory activity (Foged, 2012). Several recent papers have 
described an unspecific interferon response after administration of lipid-formulated siRNA 
molecules to mice (Hornung, 2005; Juliano, 2008). With the progress of lipids based 
systems for delivering siRNA, more and more biological side-effects may reveal; the safety 
profiles of cationic lipids and lipid-based delivery systems must be further investigated. This 
is especially true for the lipidoids.
The structure of cationic lipids is known to affect transfection efficiency and toxicity of 
cationic lipid-based delivery systems (Lv, 2006). Therefore, novel lipids with high 
transfection efficiency and low toxicity are highly pursued in research. Although lipids with 
pH sensitive groups are believed to improve nucleic acid delivery (Schroeder, 2009), over 20 
years of research has been completed, and a large amount of compounds has been designed 
and synthesized, barriers still remain. From our point of view, lipids (such as lipidoids), 
newly developed and with very low toxicity, should be incorporated into controlled 
assemblies with polymer (e.g. protamine), inorganic (e.g. calcium phosphate), any other 
available cores to impart specific performance functionality.
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Chemical structures of lipids with bis-(2-dimethylaminoethane) and mono-(2-
dimethylaminoethane) as head groups.
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Chemical structures of CMVL4 and CMVL5.
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Chemical structures of CHOSS-4N.
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Chemical structure of DLin-KC2-DMA.
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Synthesis schematic of lipidoids by the conjugate addition of amine to α,β-unsaturated 
carbonyl compounds.
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Chemical structure of 98N12-5(1).
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Synthesis schematic of lipidoids by the conjugate addition of amine to epoxides.
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Synthesis schematic of lipidoids by the conjugate addition of amine to lipid-like tails 
containing hydroxyl, carbamate, ether, or amine functional groups.
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